These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 29444895)

  • 1. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.
    Messer LH; Forlenza GP; Sherr JL; Wadwa RP; Buckingham BA; Weinzimer SA; Maahs DM; Slover RH
    Diabetes Care; 2018 Apr; 41(4):789-796. PubMed ID: 29444895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
    Stone MP; Agrawal P; Chen X; Liu M; Shin J; Cordero TL; Kaufman FR
    Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Real-Life Usage of MiniMed 670G Automode in Children with Type 1 Diabetes Less than 7 Years Old.
    Salehi P; Roberts AJ; Kim GJ
    Diabetes Technol Ther; 2019 Aug; 21(8):448-451. PubMed ID: 31166801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
    Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
    Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study.
    Lee MH; Vogrin S; Paldus B; Jones HM; Obeyesekere V; Sims C; Wyatt SA; Ward GM; McAuley SA; MacIsaac RJ; Krishnamurthy B; Sundararajan V; Jenkins AJ; O'Neal DN
    Diabetes Technol Ther; 2019 Sep; 21(9):499-506. PubMed ID: 31264889
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.
    Garg SK; Weinzimer SA; Tamborlane WV; Buckingham BA; Bode BW; Bailey TS; Brazg RL; Ilany J; Slover RH; Anderson SM; Bergenstal RM; Grosman B; Roy A; Cordero TL; Shin J; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2017 Mar; 19(3):155-163. PubMed ID: 28134564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
    Mameli C; Smylie GM; Galati A; Rapone B; Cardona-Hernandez R; Zuccotti G; Delvecchio M
    Eur J Pediatr; 2023 May; 182(5):1949-1963. PubMed ID: 36809498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
    Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M;
    Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System.
    Lal RA; Basina M; Maahs DM; Hood K; Buckingham B; Wilson DM
    Diabetes Care; 2019 Dec; 42(12):2190-2196. PubMed ID: 31548247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study.
    Paldus B; Lee MH; Jones HM; McAuley SA; Horsburgh JC; Roem KL; Ward GM; MacIsaac RJ; Cohen N; Colman PG; Jenkins AJ; O'Neal DN
    Diabetes Technol Ther; 2019 Jan; 21(1):56-58. PubMed ID: 30620641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes.
    Petrovski G; Al Khalaf F; Campbell J; Fisher H; Umer F; Hussain K
    Acta Diabetol; 2020 Jun; 57(6):681-687. PubMed ID: 31953687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.
    Forlenza GP; Pinhas-Hamiel O; Liljenquist DR; Shulman DI; Bailey TS; Bode BW; Wood MA; Buckingham BA; Kaiserman KB; Shin J; Huang S; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2019 Jan; 21(1):11-19. PubMed ID: 30585770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast-Acting Insulin Aspart Use with the MiniMed
    Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
    Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol.
    McAuley SA; de Bock MI; Sundararajan V; Lee MH; Paldus B; Ambler GR; Bach LA; Burt MG; Cameron FJ; Clarke PM; Cohen ND; Colman PG; Davis EA; Fairchild JM; Hendrieckx C; Holmes-Walker DJ; Horsburgh JC; Jenkins AJ; Kaye J; Keech AC; King BR; Kumareswaran K; MacIsaac RJ; McCallum RW; Nicholas JA; Sims C; Speight J; Stranks SN; Trawley S; Ward GM; Vogrin S; Jones TW; O'Neal DN
    BMJ Open; 2018 Jun; 8(6):e020274. PubMed ID: 29886443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy of Basal Rate and Carbohydrate Ratio Learning Algorithm for Closed-Loop Insulin Delivery (Artificial Pancreas) in Youth with Type 1 Diabetes in a Diabetes Camp.
    Palisaitis E; El Fathi A; Von Oettingen JE; Krishnamoorthy P; Kearney R; Jacobs P; Rutkowski J; Legault L; Haidar A
    Diabetes Technol Ther; 2020 Mar; 22(3):185-194. PubMed ID: 31596127
    [No Abstract]   [Full Text] [Related]  

  • 18. Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study.
    Forlenza GP; Vigers T; Berget C; Messer LH; Lal RA; Basina M; Maahs DM; Hood K; Buckingham B; Wilson DM; Wadwa RP; Driscoll KA; Pyle L
    Diabetes Technol Ther; 2022 Mar; 24(3):157-166. PubMed ID: 34780306
    [No Abstract]   [Full Text] [Related]  

  • 19. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.
    Wood MA; Shulman DI; Forlenza GP; Bode BW; Pinhas-Hamiel O; Buckingham BA; Kaiserman KB; Liljenquist DR; Bailey TS; Shin J; Huang S; Chen X; Cordero TL; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2018 Nov; 20(11):731-737. PubMed ID: 30299976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed
    Cordero TL; Garg SK; Brazg R; Bailey TS; Shin J; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2017 Dec; 19(12):749-752. PubMed ID: 29148821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.